{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:01:15Z","timestamp":1769054475263,"version":"3.49.0"},"reference-count":19,"publisher":"American Diabetes Association","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":2941,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>The 200 units\/mL formulation of insulin degludec (IDeg 200 units\/mL) contains equal units of insulin in half the volume compared with the 100 units\/mL formulation. We compared the efficacy and safety of IDeg 200 units\/mL once daily with 100 units\/mL insulin glargine (IGlar) in insulin-na\u00efve subjects with type 2 diabetes (T2DM) inadequately controlled with oral antidiabetic drugs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>In this 26-week, open-label, treat-to-target trial, subjects (n = 457; mean HbA1c 8.3% [67 mmol\/mol], BMI 32.4 kg\/m2, and fasting plasma glucose [FPG] 9.6 mmol\/L [173.2 mg\/dL]) were randomized to IDeg 200 units\/mL or IGlar, both given once daily in combination with metformin with or without a dipeptidyl peptidase-4 inhibitor. Basal insulin was initiated at 10 units\/day and titrated weekly to an FPG target of &amp;lt;5 mmol\/L (&amp;lt;90 mg\/dL) according to mean prebreakfast self-measured blood glucose values from the preceding 3 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>By 26 weeks, IDeg reduced HbA1c by 1.30% and was not inferior to IGlar. Mean observed FPG reductions were significantly greater with IDeg than IGlar (\u22123.7 vs. \u22123.4 mmol\/L [\u201367 vs. \u201361 mg\/dL]; estimated treatment difference: \u22120.42 [95% CI \u22120.78 to \u22120.06], P = 0.02). Despite this difference, rates of overall confirmed hypoglycemia were not higher with IDeg than with IGlar (1.22 and 1.42 episodes\/patient-year, respectively), as were rates of nocturnal confirmed hypoglycemia (0.18 and 0.28 episodes\/patient-year, respectively). Mean daily basal insulin dose was significantly lower by 11% with IDeg 200 units\/mL compared with IGlar. IDeg was well-tolerated, and the rate of treatment-emergent adverse events was similar across groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In this treat-to-target trial in insulin-na\u00efve patients with T2DM, IDeg 200 units\/mL improved glycemic control similarly to IGlar with a low risk of hypoglycemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc12-2329","type":"journal-article","created":{"date-parts":[[2013,5,29]],"date-time":"2013-05-29T04:23:43Z","timestamp":1369801423000},"page":"2536-2542","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":126,"title":["Low-Volume Insulin Degludec 200 Units\/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Na\u00efve Patients With Type 2 Diabetes"],"prefix":"10.2337","volume":"36","author":[{"given":"Stephen C.L.","family":"Gough","sequence":"first","affiliation":[{"name":"Oxford Centre for Diabetes, Endocrinology and Metabolism and NIHR Oxford Biomedical Research Centre, Oxford, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Iowa Diabetes and Endocrinology Center, Des Moines, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Jain","sequence":"additional","affiliation":[{"name":"Aurora Advanced Healthcare, Milwaukee, Wisconsin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henriette","family":"Mersebach","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Rasmussen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[{"name":"International Diabetes Center at Park Nicollet, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2013,8,13]]},"reference":[{"key":"2022031301592002100_B1","unstructured":"Obesity Society. Your weight and diabetes, 2010 [article online]. Available from: http:\/\/www.obesity.org\/resources-for\/your-weight-and-diabetes.htm. Accessed 9 February 2012"},{"key":"2022031301592002100_B2"},{"key":"2022031301592002100_B3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4158\/EP.15.1.71","article-title":"High-dose insulin therapy: is it time for U-500 insulin?","volume":"15","author":"Lane","year":"2009","journal-title":"Endocr Pract"},{"key":"2022031301592002100_B4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/pgmj.2008.073379","article-title":"Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus","volume":"85","author":"Crasto","year":"2009","journal-title":"Postgrad Med J"},{"key":"2022031301592002100_B5"},{"key":"2022031301592002100_B6"},{"key":"2022031301592002100_B7"},{"key":"2022031301592002100_B8","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031301592002100_B9","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0140-6736(12)60204-9","article-title":"1 Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Heller","year":"2012","journal-title":"Lancet"},{"key":"2022031301592002100_B10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet"},{"key":"2022031301592002100_B11","first-page":"403","article-title":"Declaration of Helsinki. Ethical principles for medical research involving human subjects","volume":"107","author":"World Medical Association Inc","year":"2009","journal-title":"J Indian Med Assoc"},{"key":"2022031301592002100_B12","first-page":"199","article-title":"ICH harmonised tripartite guideline: guideline for good clinical practice","volume":"47","year":"2001","journal-title":"J Postgrad Med"},{"key":"2022031301592002100_B13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","article-title":"Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia","volume":"28","author":"Workgroup on Hypoglycemia, American Diabetes Association","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031301592002100_B14","volume-title":"Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention","author":"Cryer","year":"2009"},{"key":"2022031301592002100_B15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/DMSO.S29367","article-title":"Uncovering undetected hypoglycemic events","volume":"5","author":"Unger","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2022031301592002100_B16","first-page":"120","article-title":"Diabetes care\u2014insulin delivery in a changing world","volume":"10","author":"Marcus","year":"2008","journal-title":"Medscape J Med"},{"key":"2022031301592002100_B17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabet Med"},{"key":"2022031301592002100_B18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0145721709345773","article-title":"Barriers to insulin injection therapy: patient and health care provider perspectives","volume":"35","author":"Rubin","year":"2009","journal-title":"Diabetes Educ"},{"key":"2022031301592002100_B19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/dmrr.709","article-title":"U-500 insulin: why, when and how to use in clinical practice","volume":"23","author":"Garg","year":"2007","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/9\/2536\/620441\/2536.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/36\/9\/2536\/620441\/2536.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T06:05:41Z","timestamp":1647151541000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/36\/9\/2536\/37903\/Low-Volume-Insulin-Degludec-200-Units-mL-Once"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,13]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,8,13]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc12-2329","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,13]]}}}